Avanafil
- Generic Name
- Avanafil
- Brand Names
- Spedra, Stendra
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26ClN7O3
- CAS Number
- 330784-47-9
- Unique Ingredient Identifier
- DR5S136IVO
- Background
Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both sildenafil and vardenafil but less selectivity than tadalafil, suggesting a relatively lower risk of visual disturbances associated with off-target PDE6 inhibition.
It first received FDA approval on April 27, 2012, with subsequent EMA approval in June 2013.
- Indication
Avanafil is indicated for the treatment of erectile dysfunction.
- Associated Conditions
- Erectile Dysfunction
- Associated Therapies
- -
Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction
- First Posted Date
- 2009-03-02
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 712
- Registration Number
- NCT00853606
- Locations
- 🇺🇸
Research Site, Spring, Texas, United States
Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 390
- Registration Number
- NCT00809471
- Locations
- 🇺🇸
Research Site, Spring, Texas, United States
Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2012-07-11
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 646
- Registration Number
- NCT00790751
- Locations
- 🇺🇸
Research Site, Spring, Texas, United States
To Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2009-12-02
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 44
- Registration Number
- NCT00770042
- Locations
- 🇺🇸
Research Site, Lincoln, Nebraska, United States
A Thorough EKG Safety Study of TA-1790 (Avanafil)
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2011-01-07
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 57
- Registration Number
- NCT00769041
- Locations
- 🇺🇸
Covance Phase 1 Clinical Unit, Madison, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.